Bridgewater Associates and ARK Invest Both Hold Eli Lilly and Nvidia
Ray Dalio's Bridgewater Associates and Cathie Wood's ARK Invest, despite differing investment strategies, both held significant stakes in Eli Lilly (LLY) and Nvidia (NVDA) as of the second quarter. Bridgewater increased its position in LLY to 87,023 shares valued at $104.4 million while reducing its NVDA stake by nearly a million shares. ARK added heavily to both stocks—64,578 shares in LLY and over 345,000 in NVDA—with total holdings of approximately $92.7 million and $276.4 million respectively. Eli Lilly's stock is seen as a growth opportunity due to strong performance from its obesity and diabetes treatments Mounjaro and Zepbound, which drove 48% year-over-year revenue growth in Q2. However, the company’s high valuation raises concerns among bears who argue that much of this potential may already be priced into the stock. Nvidia remains a key focus for both firms due to its role in AI innovation, though Bridgewater's larger stake suggests more confidence or exposure compared to ARK.
Topics: ARK Invest Bridgewater Associates Eli Lilly (LLY) Nvidia (NVDA) stock holdings